PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Multiparametric MRI detects more local recurrences after prostatectomy than prostate-specific membrane antigen PET-CT, with the two showing only moderate agreement.

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection. The Food and Drug Administration (FDA) ...

Study findings support PSMA-PET as a first-line approach for the primary staging of intermediate- to high-risk prostate cancer. In head-to-head comparisons, prostate-specific membrane antigen positron ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., ...

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, ...